[144] BeOne Medicines Ltd. American SEC Filing

Rhea-AI Filing Summary

BeOne Medicines Ltd. (symbol: ONC) filed a Form 144 indicating a planned disposition of American Depositary Shares (ADSs) by shareholder Lai Wang.

• Securities to be sold: 1,028 ADSs
• Aggregate market value: US $267,280
• Approximate sale date: 23 June 2025
• Exchange: NASDAQ
• Total ADSs outstanding: 109,600,154 (proposed sale equals ≈0.0009 %)

The filing also discloses that the same shareholder sold 3,049 ADSs during the prior three-month period, generating gross proceeds of US $785,552.36 across three transactions dated 6 June, 16 June, and 17 June 2025.

The shares to be sold were acquired through restricted-stock vesting under a registered plan on 22 June 2025; full payment was made in stock ("Not Applicable" cash consideration). Morgan Stanley Smith Barney LLC is listed as the executing broker.

The company’s Rule 144 notice states that the seller attests to having no undisclosed material adverse information about the issuer at the time of filing.

Investor takeaway: The proposed sale represents a very small fraction of total shares outstanding. While repeated sales may signal individual liquidity preferences, the size is unlikely to be financially material to BeOne Medicines’ float or trading dynamics.

Positive

• None.

Negative

• Repeated planned and recent sales by shareholder Lai Wang total 4,077 ADSs within June 2025, which, while numerically minor, may be perceived as insider selling pressure.

Insights

Securities Analyst

TL;DR: Immaterial insider-sized sale; negligible float impact.

The 1,028-share sale (≈US $267k) plus recent 3,049-share prior sales total roughly US $1.05 million. Relative to 109.6 million ADSs outstanding, combined disposals amount to <0.004 %. Volume is too small to meaningfully affect market liquidity or valuation. No information on the seller’s role was provided, so motivation remains unknown. Overall market impact appears neutral; however, monitoring continued filings may help detect any emerging selling trend.

Corporate Governance Expert

TL;DR: Repeated share sales could raise mild governance questions.

Although the dollar value is minor, three prior Form 144-reportable sales in June plus this notice suggest consistent offloading by the same shareholder. Without disclosure of the individual’s relationship to BeOne Medicines, investors cannot gauge whether strategic leadership is exiting or this is routine diversification. While not material in size, ongoing insider activity often precedes sentiment shifts and merits watchfulness.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
ADS	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1028	267280.00	109600154	06/23/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
ADS	06/22/2025	Restricted stock vesting under a registered plan	Issuer			1028	06/22/2025	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
LAI WANG 94 Solaris Avenue, Camana Bay Grand Cayman E9 KY1 1108	ADS	06/17/2025	470	118141.55
LAI WANG 94 Solaris Avenue, Camana Bay Grand Cayman E9 KY1 1108	ADS	06/16/2025	1177	313557.51
LAI WANG 94 Solaris Avenue, Camana Bay Grand Cayman E9 KY1 1108	ADS	06/06/2025	1402	353853.30

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does BeOne Medicines' Form 144 filed on 23-Jun-2025 disclose?

It notifies the SEC of a planned sale of 1,028 ADSs valued at US $267,280 on NASDAQ around 23 June 2025.

How many BeOne Medicines (ONC) shares has Lai Wang sold recently?

The filing lists 3,049 ADSs sold between 6-Jun-2025 and 17-Jun-2025, plus the newly proposed 1,028 ADSs.

What percentage of outstanding ONC ADSs does the proposed sale represent?

Approximately 0.0009 % of the company’s 109,600,154 ADSs outstanding.

Who is the broker executing the planned sale for BeOne Medicines' shareholder?

Morgan Stanley Smith Barney LLC Executive Financial Services, New York, is listed as the broker.

Did the shareholder pay cash for the shares being sold?

No. The ADSs were acquired through restricted-stock vesting; the nature of payment is marked "Not Applicable."